MDx Firm Biocartis Raises $15M in Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis has raised €10 million ($14.9 million) in a Series A financing round that included a handful of European investment firms.

The Lausanne, Switzerland-based firm is developing a multiplex, molecular diagnostics platform that will be able to quantify and amplify bio-analytes, such as proteins, nucleic acids, and small molecules. The firm said that it will use the proceeds from the private offering to develop a commercial version of its proprietary platform, as well as its first prototype assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.